UNSPSC 51171854: Ramosetron

This classification denotes a 5-ht3 receptor antagonist and antiemetic agent with the molecular formula C17H17N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7ZRO0SC54Y, chemically known as (-)-(r)-1-methylindol-3-yl-4,5,6,7-tetrahydro-5-benzimidazolyl ketone. but generally known as ramosetron, which bears US NIH Compound Identifier 108000. European Medicines Agency schedules Ramosetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10254MIG.

UNSPSC 51171854 Ramosetron is a Commodity code representing a specific antiemetic pharmaceutical, yet recent state and local solicitations tagged with this code reflect broader pharmaceutical procurement activity rather than ramosetron-specific purchasing. The source shows three recent opportunities spanning offender drug testing services, a therapeutic pharmacy initiative exploratory request, and a multistate cooperative generic pharmaceuticals contract — none of which specify ramosetron as a line item. State and local governments appear to procure this code primarily through consolidated pharmaceutical purchasing frameworks and cooperative agreements rather than direct commodity orders. Issuing bodies include county criminal-justice departments (Collin County Community Supervision and Corrections Department in Texas), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities).

Recent activity concentrates in Texas and the upper Midwest. The Collin County RFP 2026-327, due July 23, 2026, solicits offender specimen collection and drug testing services with an estimated contract value of $600,000 and a two-year initial term with optional three one-year renewals. The Texas HHS Commission issued RFI HHS0017013 in March 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, with no award value specified at that exploratory stage. The Minnesota Department of Administration's MMCAP cooperative procurement (S1070000015802, due March 26, 2026) established multiple contracts for generic pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026 and contract terms extending through June 30, 2028. The code shows limited direct activity; ramosetron appears to be sourced through these broader pharmaceutical supply agreements rather than as a standalone commodity under state and local RFPs.